Open AccessComparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis
Author(s) -
Imtiaz A. Samjoo,
Evelyn Worthington,
Christopher Drudge,
Melody Zhao,
Chris Cameron,
Dieter A. Häring,
Dee Stoneman,
Luisa Klotz,
Nicholas Adlard
Publication year - 2020
Publication title -
journal of comparative effectiveness research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.567
H-Index - 23
eISSN - 2042-6313
pISSN - 2042-6305
DOI - 10.2217/cer-2020-0122
Subject(s) - ofatumumab , medicine , natalizumab , ocrelizumab , alemtuzumab , multiple sclerosis , meta analysis , oncology , disease , immunology , rituximab , transplantation , lymphoma
Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was conducted to determine the relative effect of ofatumumab on annualized relapse rate and confirmed disability progression at 3 months and 6 months. Results: For each outcome, ofatumumab was as effective as other highly efficacious monoclonal antibody DMTs (i.e., alemtuzumab, natalizumab and ocrelizumab). Conclusion: Ofatumumab offers beneficial outcomes for RMS by reducing relapse and disability progression risk.